| The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers IR Eissa, I Bustos-Villalobos, T Ichinose, S Matsumura, Y Naoe, ... Cancers 10 (10), 356, 2018 | 174 | 2018 |
| Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials IR Eissa, Y Naoe, I Bustos-Villalobos, T Ichinose, M Tanaka, W Zhiwen, ... Frontiers in oncology 7, 149, 2017 | 91 | 2017 |
| Combination of cetuximab and oncolytic virus canerpaturev synergistically inhibits human colorectal cancer growth Z Wu, T Ichinose, Y Naoe, S Matsumura, IB Villalobos, IR Eissa, ... Molecular Therapy-Oncolytics 13, 107-115, 2019 | 24 | 2019 |
| The impact of metformin on tumor-infiltrated immune cells: preclinical and clinical studies M Abdelmoneim, MA Aboalela, Y Naoe, S Matsumura, IR Eissa, ... International Journal of Molecular Sciences 24 (17), 13353, 2023 | 23 | 2023 |
| Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+PD‐1− tumor‐infiltrating T cells in PD‐L1‐enriched tumor microenvironment IR Eissa, N Mukoyama, M Abdelmoneim, Y Naoe, S Matsumura, ... International journal of cancer 149 (1), 214-227, 2021 | 14 | 2021 |
| C-REV retains high infectivity regardless of the expression levels of cGAS and STING in cultured pancreatic cancer cells D Morimoto, S Matsumura, I Bustos-Villalobos, PA Sibal, T Ichinose, ... Cells 10 (6), 1502, 2021 | 8 | 2021 |
| Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model M Abdelmoneim, IR Eissa, MA Aboalela, Y Naoe, S Matsumura, PA Sibal, ... Scientific Reports 12 (1), 21570, 2022 | 6 | 2022 |
| The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers. Cancers 10 (10): 356 I Eissa, I Bustos-Villalobos, T Ichinose, S Matsumura, Y Naoe, N Miyajima, ... | 4 | 2018 |
| Dendritic cells generated from naïve and tumor-bearing mice uniquely restores different leukocyte subpopulations in chemotherapy-treated tumor-bearing mice M Salem, I Eissa, T Mohamed Clinical Cancer Investigation Journal 5 (1-2016), 1-10, 2016 | 4 | 2016 |
| Precision-Cut Liver Slices as an ex vivo model to evaluate antifibrotic therapies for liver fibrosis and cirrhosis Y Wang, B Leaker, G Qiao, M Sojoodi, IR Eissa, ET Epstein, J Eddy, ... bioRxiv, 2023 | 3 | 2023 |
| S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model Nagoya Journal of Medical Science 83 (4), 683–696, 2021 | 3 | 2021 |
| Precision-cut liver slices as an ex vivo model to evaluate antifibrotic therapies for liver fibrosis and cirrhosis Y Wang, B Leaker, G Qiao, M Sojoodi, IR Eissa, ET Epstein, J Eddy, ... Hepatology Communications 8 (11), e0558, 2024 | 2 | 2024 |
| STING activator 2′ 3′‐cGAMP enhanced HSV‐1‐based oncolytic viral therapy PA Sibal, S Matsumura, T Ichinose, I Bustos‐Villalobos, D Morimoto, ... Molecular Oncology 18 (5), 1259-1277, 2024 | 1 | 2024 |
| Oncolytic herpes simplex virus HF10 (canerpaturev, C-REV) promotes accumulation of CD8+ PD-1-tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment IR Eissa, N Mukoyama, M Abdelmoneim, Y Naoe, S Matsumura, ... International journal of cancer, 2021 | 1 | 2021 |
| The ITGA2 (CD49b) collagen receptor excludes the CD8+ T cell infiltration in pancreatic ductal adenocarcinoma IR Eissa, ED Abston, D Kuruppu, Y Wang, G Qiao, M Qadan, M Lanuti, ... Cancer Research 84 (6_Supplement), 4271-4271, 2024 | | 2024 |
| Chimeric target factor receptor H Kasuya, Y Naoe, S Matsumura, IRN Eissa, MAAALI MOHAMED US Patent App. 18/272,430, 2024 | | 2024 |
| Chimeric target factor receptor H Kasuya, Y Naoe, S Matsumura, IRN EISSA, MAAALI MOHAMED | | 2023 |
| Combination drug for treating malignant tumor, pharmaceutical composition for treating malignant tumor, and pharmaceutical composition for malignant tumor treatment H Kasuya, Y Naoe, S Matsumura, IRN Eissa US Patent App. 17/631,808, 2022 | | 2022 |
| Oncolytic HSV HF10 (canerpaturev, C-REV) promotes accumulation of CD8+ PD-1-tumor-infiltrating T cells in a SCC model AA Mohamed, IR Eissa, N Mukoyama, M Abdelmoneim, Y Naoe, ... CANCER SCIENCE 113, 526-526, 2022 | | 2022 |
